Avicanna Inc AVCN

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the September 17th Life Sciences Virtual Investor Forum are available for on-demand viewing. The event featured live presentations from executives representing innovative clinical-stage and commercial companies across the life sciences sector. REGIS

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that Aras Azadian, CEO of Avicanna Inc. and Avicanna Inc. will be presenting live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026. The event will be conducted as a live, interactive online forum, offering investors and industry professi

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that Aras Azadian, CEO of Avicanna Inc will present live at the Life Scien

Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live from investors.NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Forum taking place on September 17, 2026. REGISTER HERE Individual investors, institutional investors, advisors, and analysts are invited to attend. It is rec

Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in CanadaTORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce the MyMedi.ca Integrated Healthcare Program (“Program”), a new program designed to integrate medical cannabis care and pati

Strategic investment by pharmaceutical executive and life sciences investor Michael PorterTORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement. “Having spent my career building and investing in specialty-pharm

Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, today announced the introduction of its proprietary

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role o

FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products. The investment represents a strategic capital allocation aligned with Splash's previously announced transformation into a cannabinoid-based health,

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, June 12, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has close

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansionContinued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its finan

TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 2, 2026 (“Circular”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders

TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is announces that Eileen McCormack, who was not on the slate of directors for re-election or election as outlined in the circular at the upcoming annual general and special meeting of shareholders scheduled for Thursday May 7, 2026, has tend

Rescheduling aligns with Avicanna’s established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, applauds the announcement by the U.S. D

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that as previously disclosed its annual general and special meeting of shareholders will be held virtually on Thursday, May 7, 2026 at 11:30 AM (Toronto Time). Materials for the meeting will be available under the Co

ThreeD Capital (IDK.CN) after markets closed on Tuesday said that through a series of transactions e

TORONTO, April 07, 2026 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that through a series of transactions ending in recent weeks (the “Dispositions”), ThreeD disposed of ownership and control of an aggregate of 977,000 common shares (the “Subject Shares”) of Avicanna Inc. (the “Company” or “AVCN”). The Subjec